血皮斯塔丁的降低与患有基本高血压的患者的临床参数有关
Wenjia Chen1, Yu Fu1, Yuanyuan Jin1
1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Peptides
|April 20, 2024
概括
高血压患者的血皮质素 (CST) 水平较低,这表明CST可能是管理高血压和改善血压控制的保护性标.
科学领域:
- 心血管研究研究心血管研究
- 内分泌学 在内分泌学.
- 高血压研究 高血压研究
背景情况:
- 皮质他 (CST) 是一种具有已知的心血管保护作用的内源性多.
- 在高血压的背景下,CST的具体作用尚未得到充分证实.
- 在高血压患者中调查CST水平对于了解其潜在参与至关重要.
研究的目的:
- 为了确定与正常血压个体相比,在患有基本高血压的患者中血中CST水平.
- 探索血中CST水平与血压之间的相关性.
- 分析CST和代谢参数之间的关系,以及心脏结构/功能.
主要方法:
- 一项医院研究,涉及81名基本高血压患者和75名高血压患者.
- 使用酶相关免疫吸收试验 (ELISA) 测量血中CST水平.
- 收集有关血压,代谢指标 (TC,TG,FGB,Scr) 和心脏参数的数据.
主要成果:
- 与对照组相比,高血压患者的血CST水平明显较低.
- 患有高血压且血压无法控制的高血压患者表现出较低的CST水平,而不是控制血压的患者.
- 血CST与缩血压 (SBP) 和血清肌素 (Scr) 有显著的负相关性.
结论:
- 循环中CST度的降低与高血压有关.
- 在高血压患者的血压控制后观察到升高的CST水平.
- CST成为潜在的内源性保护因子和高血压的治疗点.
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
Antihypertensive Drugs: Direct Renin Inhibitors
613
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
613
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Antihypertensive Drugs: Action of Diuretics
679
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
679
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422


